Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: Technology appraisal guidance [TA535] – NICE

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid